GDT can be used for: Priority access to high-end curative diabetes tourism packages Payment for medical tourism services in the UAE, Palau, and Japan Purchase of 5-ALA supplements and formulations Biomarker testing for DSC detection Online consultations with specialist physicians Additionally, 20% of tokens used for medical services are burned to reduce supply.

GDT is a pure utility token directly tied to real-world services such as curative diabetes tourism, biomarker testing, and specialist consultations. Unlike speculative tokens, it is backed by a scientific project targeting complete remission of diabetes through HDAC inhibitors, 5-ALA, and Biozipcode™ drug delivery technology. It is not a security and offers no dividends or ...

GDT is structured as a utility token for service payments and participant rewards. It is designed to avoid classification as a security in all operating jurisdictions, with legal opinions obtained though lawyers in BVI, UAE, Japan, and the U.S.

Key risks include clinical trial failure, regulatory delays, and potential declines in medical tourism demand. The project mitigates these with multi-country trials, adaptive trial designs, parallel regulatory filings, and diversified service offerings.

A total of 500 million GDT will be minted at launch, with no future issuance. Allocation includes 30% to early investors, 20% to the public sale, 20% for staking/rewards, 10% to the team, 10% to liquidity pools, and 10% to an SDG public fund.

GDT is required for payments in medical tourism, biomarker testing, and 5-ALA supplement purchases. Real-world healthcare demand ensures continuous token usage, and 20% of tokens used for medical services are permanently burned, reducing supply over time.